Variation in Prognostic Factors and Molecular Phenotype with Menopausal Status in Turkish Patients with Breast Cancer

Creative Commons License

Mutlu H., Ozdogan M., Colak T., Akca Z., Buyukcelik A.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.23, sa.2, ss.109-116, 2013 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.4999/uhod.11081
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.109-116
  • Anahtar Kelimeler: Breast cancer, Menopause, Molecular types, Prognosis, CLIMACTERIC SYMPTOMS, YOUNG AGE, SURVIVAL, SUBTYPES, RISK, EPIDEMIOLOGY, CARCINOMAS, PATTERNS, DISEASE, WOMEN
  • Akdeniz Üniversitesi Adresli: Evet

Özet

In Turkish patients with breast cancer variations of prognostic factors were examined according to the menopausal status. In addition, molecular variations were investigated according to the menopausal status. A total of 1449 patients was enrolled from Akdeniz University Hospital of Medical School and Kayseri Education and Research Hospital. The patients were divided into three groups as menopausal status (pre, peri and postmenopausal) and into four groups according to molecular types (luminal A,luminal B, HER 2 like and Unclassified-Basal like). Patients were retrospectively recorded in the SPSS software. There was significant difference in the estrogen and cerbB2 hormon receptor positivity between premenopausal and postmenopausal groups (p=0.003 and 0.032). Estrogen receptor ratio was higher in postmenopausal group, and CerbB2 receptor ratio was higher in premenopausal group. Luminal A molecular subtype was the dominant subgroup. Compared to the other two groups, in premenopausal group, the ratio of HER 2 Like and Unclassified-Basal like molecular type were higher and the ratio of the luminal types were lower. Luminal A was the dominant subgroup in Turkish patients with breast cancer. Rate of molecular types was determined to be varied with menopausal status. This variations were compatible with the poor prognosis premenopausal patients with breast cancer.